3
48
Oliván-Viguera et al.
KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood
Mishra RC, Belke D, Wulff H, and Braun AP (2013) SKA-31, a novel activator of SKCa
and IKCa channels, increases coronary flow in male and female rat hearts. Car-
diovasc Res 97:339–348.
pressure in conscious dogs. Br J Pharmacol 165:223–234.
Devor DC, Singh AK, Frizzell RA, and Bridges RJ (1996) Modulation of Cl- secretion
21
1
by benzimidazolones. I. Direct activation of a Ca -dependent K channel. Am J
Physiol 271:L775–L784.
Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar
JM, and Köhler R (2013) Novel phenolic inhibitors of small/intermediate-conductance
21
1
Díez-Barra E, García-Martínez JC, Merino S, del Rey R, Rodríguez-López J, Sánchez-
Verdú P, and Tejeda J (2001) Synthesis, characterization, and optical response of di-
polar and non-dipolar poly(phenylenevinylene) dendrimers. J Org Chem 66:5664–5670.
Diness JG, Sørensen US, Nissen JD, Al-Shahib B, Jespersen T, Grunnet M, and Hansen
Ca -activated K channels, KCa3.1 and KCa2.3. PLoS ONE 8:e58614.
Radtke J, Schmidt K, Wulff H, Köhler R, and de Wit C (2013) Activation of KCa3.1 by
SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and
hypertensive connexin40-deficient mice. Br J Pharmacol 170:293–303.
21
1
RS (2010) Inhibition of small-conductance Ca -activated K channels terminates and
protects against atrial fibrillation. Circ Arrhythm Electrophysiol 3:380–390.
Edwards G, Félétou M, and Weston AH (2010) Endothelium-derived hyperpolarising
factors and associated pathways: a synopsis. Pflugers Arch 459:863–879.
Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de
Bakker PI, Mueller M, and Lubitz SA et al. (2010) Common variants in KCNN3 are
associated with lone atrial fibrillation. Nat Genet 42:240–244.
Rosa JC, Galanakis D, Ganellin CR, Dunn PM, and Jenkinson DH (1998) Bis-quinolinium
cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane
(UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive
2
1
1
Ca -activated K channel. J Med Chem 41:2–5.
Ruggieri P, Mangino G, Fioretti B, Catacuzzeno L, Puca R, Ponti D, Miscusi M, Franciolini
F, Ragona G, and Calogero A (2012) The inhibition of KCa3.1 channels activity reduces
cell motility in glioblastoma derived cancer stem cells. PLoS ONE 7:e47825.
Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R,
and Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of
KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyper-
polarizing factor response and lowers blood pressure. Mol Pharmacol 75:281–295.
Shakkottai VG, do Carmo Costa M, Dell’Orco JM, Sankaranarayanan A, Wulff H,
and Paulson HL (2011) Early changes in cerebellar physiology accompany motor
dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci
31:13002–13014.
Engbers JD, Anderson D, Asmara H, Rehak R, Mehaffey WH, Hameed S, McKay BE,
Kruskic M, Zamponi GW, and Turner RW (2012) Intermediate conductance
calcium-activated potassium channels modulate summation of parallel fiber input
in cerebellar Purkinje cells. Proc Natl Acad Sci USA 109:2601–2606.
Félétou M, Köhler R, and Vanhoutte PM (2010) Endothelium-derived vasoactive
factors and hypertension: possible roles in pathogenesis and as treatment targets.
Curr Hypertens Rep 12:267–275.
Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999)
Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401:493–497.
Ge ZD, Zhang XH, Fung PC, and He GW (2000) Endothelium-dependent hyperpo-
larization and relaxation resistance to N(G)-nitro-L-arginine and indomethacin in
coronary circulation. Cardiovasc Res 46:547–556.
Soder RP, Parajuli SP, Hristov KL, Rovner ES, and Petkov GV (2013) SK channel-selective
opening by SKA-31 induces hyperpolarization and decreases contractility in human uri-
nary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 304:R155–R163.
Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen
S, Demnitz J, and Wulff H et al. (2013) NS6180, a new KCa3.1 channel inhibitor
prevents T-cell activation and inflammation in a rat model of inflammatory bowel
disease. Br J Pharmacol 168:432–444.
Grgic I, Eichler I, Heinau P, Si H, Brakemeier S, Hoyer J, and Köhler R (2005)
2
1
1
Selective blockade of the intermediate-conductance Ca -activated K channel
suppresses proliferation of microvascular and macrovascular endothelial cells and
angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25:704–709.
Taylor MS, Bonev AD, Gross TP, Eckman DM, Brayden JE, Bond CT, Adelman JP,
2
1
1
and Nelson MT (2003) Altered expression of small-conductance Ca -activated K
SK3) channels modulates arterial tone and blood pressure. Circ Res 93:124–131.
Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt
C, and Raman G et al. (2009) Renal fibrosis is attenuated by targeted disruption of
KCa3.1 potassium channels. Proc Natl Acad Sci USA 106:14518–14523.
(
Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, and Bowles DK (2008) Local
delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced
coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler
Thromb Vasc Biol 28:1084–1089.
Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz
MJ, Auperin DD, and Chandy KG (1994) Pharmacological characterization of five
1
cloned voltage-gated K channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably
Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson
DL, Das S, and Melvin JE et al. (2008) The intermediate-conductance calcium-
activated potassium channel KCa3.1 contributes to atherogenesis in mice and
humans. J Clin Invest 118:3025–3037.
expressed in mammalian cell lines. Mol Pharmacol 45:1227–1234.
Hougaard C, Hammami S, Eriksen BL, Sørensen US, Jensen ML, Strøbæk D,
and Christophersen P (2012) Evidence for a common pharmacological interaction
site on KCa2 channels providing both selective activation and selective inhibition of
the human KCa2.1 subtype. Mol Pharmacol 81:210–219.
Tuteja D, Xu D, Timofeyev V, Lu L, Sharma D, Zhang Z, Xu Y, Nie L, Vázquez AE,
21
and Young JN et al. (2005) Differential expression of small-conductance Ca -ac-
Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, and Maylie J (1997) A
human intermediate conductance calcium-activated potassium channel. Proc Natl
Acad Sci USA 94:11651–11656.
Jenkins DP, Strøbæk D, Hougaard C, Jensen ML, Hummel R, Sørensen US, Christophersen
P, and Wulff H (2011) Negative gating modulation by (R)-N-(benzimidazol-2-yl)-
1
tivated K channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes.
Am J Physiol Heart Circ Physiol 289:H2714–H2723.
Valero MS, Pereboom D, Barcelo-Batllory S, Brines L, Garay RP, and Alda JO (2011)
Protein kinase A signalling is involved in the relaxant responses to the selective
b-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in
vitro. J Pharm Pharmacol 63:222–229.
1
,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore
vestibule: Pharmacological evidence of deep-pore gating of KCa2 channels. Mol
Pharmacol 79:899–909.
Kaushal V, Koeberle PD, Wang Y, and Schlichter LC (2007) The Ca -activated
K
Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, Castle
N, Bradding P, and Snibson K (2013) KCa3.1 channel-blockade attenuates airway
pathophysiology in a sheep model of chronic asthma. PLoS ONE 8:e66886.
Vandorpe DH, Shmukler BE, Jiang L, Lim B, Maylie J, Adelman JP, de Franceschi L,
Cappellini MD, Brugnara C, and Alper SL (1998) cDNA cloning and functional
2
1
1
channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent
neurodegeneration. J Neurosci 27:234–244.
Köhler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, Maylie J, and Adelman
JP (1996) Small-conductance, calcium-activated potassium channels from mam-
malian brain. Science 273:1709–1714.
21
1
characterization of the mouse Ca -gated K channel, mIK1. Roles in regulatory
volume decrease and erythroid differentiation. J Biol Chem 273:21542–21553.
Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, and Wulff H (2005) In-
ternational Union of Pharmacology. LII. Nomenclature and molecular relation-
ships of calcium-activated potassium channels. Pharmacol Rev 57:463–472.
Werkman TR, Kawamura T, Yokoyama S, Higashida H, and Rogawski MA (1992)
Charybdotoxin, dendrotoxin and mast cell degranulating peptide block the voltage-
Köhler R, Degenhardt C, Kühn M, Runkel N, Paul M, and Hoyer J (2000) Expression
2
1
1
and function of endothelial Ca -activated K channels in human mesenteric ar-
tery: A single-cell reverse transcriptase-polymerase chain reaction and electro-
physiological study in situ. Circ Res 87:496–503.
Köhler R, Kaistha BP, and Wulff H (2010) Vascular KCa-channels as therapeutic targets
in hypertension and restenosis disease. Expert Opin Ther Targets 14:143–155.
Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H,
and Wibawa J et al. (2003) Blockade of the intermediate-conductance calcium-activated
potassium channel as a new therapeutic strategy for restenosis. Circulation 108:1119–1125.
Lam J, Coleman N, Garing AL, and Wulff H (2013) The therapeutic potential of
small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.
Expert Opin Ther Targets 17:1203–1220.
Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller
LM, Oliván-Viguera A, Rabjerg M, Wulff H, and Köhler R (2012) Genetic KCa3.1-
deficiency produces locomotor hyperactivity and alterations in cerebral monoamine
levels. PLoS ONE 7:e47744.
1
activated K current of fibroblast cells stably transfected with NGK1 (Kv1.2) K1
channel complementary DNA. Neuroscience 50:935–946.
Wulff H and Castle NA (2010) Therapeutic potential of KCa3.1 blockers: an overview
of recent advances, and promising trends. Expert Rev Clin Pharmacol 3:385–396.
Wulff H, Gutman GA, Cahalan MD, and Chandy KG (2001) Delineation of the
clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-
activated potassium channel, IKCa1. J Biol Chem 276:32040–32045.
Wulff H and Köhler R (2013) Endothelial small- and intermediate-conductance KCa
channels: an update on their pharmacology and usefulness as cardiovascular tar-
gets. J Cardiovasc Pharmacol 61:102–112.
Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, and Shakkottai V
(
2007) Modulators of small- and intermediate-conductance calcium-activated potas-
Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutière F, Wauthoz N, Neven P,
Ingrassia L, Antwerpen PV, and Lefranc F et al. (2010) Simple di- and trivanillates
exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli.
Bioorg Med Chem 18:3823–3833.
sium channels and their therapeutic indications. Curr Med Chem 14:1437–1457.
Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, and Chandy KG (2000) Design of
a potent and selective inhibitor of the intermediate-conductance Ca -activated K channel,
IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 97:8151–8156.
Zhang M, Pascal JM, Schumann M, Armen RS, and Zhang JF (2012) Identification
of the functional binding pocket for compounds targeting small-conductance
Ca -activated potassium channels. Nat Commun 3:1021.
Zhang Q, Timofeyev V, Lu L, Li N, Singapuri A, Long MK, Bond CT, Adelman JP,
and Chiamvimonvat N (2008) Functional roles of a Ca -activated K (SK2)
21
1
Li N, Timofeyev V, Tuteja D, Xu D, Lu L, Zhang Q, Zhang Z, Singapuri A, Albert TR,
21
1
and Rajagopal AV et al. (2009) Ablation of a Ca -activated K channel (SK2
channel) results in action potential prolongation in atrial myocytes and atrial fi-
brillation. J Physiol 587:1087–1100.
21
Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and
computational approaches to estimate solubility and permeability in drug discov-
ery and development settings. Adv Drug Deliv Rev 46:3–26.
21
1
channel in atrioventricular nodes. Circ Res 102:465–471.
Meseguer V, Karashima Y, Talavera K, D’Hoedt D, Donovan-Rodríguez T, Viana F,
Nilius B, and Voets T (2008) Transient receptor potential channels in sensory
neurons are targets of the antimycotic agent clotrimazole. J Neurosci 28:576–586.
Address correspondence to: Ralf Köhler, Unidad de Investigación Trasla-
cional, Instituto Aragonés de Ciencias de la Salud (I1CS), Hospital Universitario
Milkau M, Köhler R, and de Wit C (2010) Crucial importance of the endothelial
1
K
channel SK3 and connexin40 in arteriolar dilations during skeletal muscle
contraction. FASEB J 24:3572–3579.